

Client: ARUP Example Report Only
500 Chipeta Way
Salt Lake City, UT 84108
UNITED STATES

Physician: TEST, TEST

Patient: PATIENT, POS TEST

DOB: 1/1/1985
Sex: Female
Patient Identifiers: 39634
Visit Number (FIN): 39957
Collection Date: 6/21/2022 15:39

Epidermal Transglutaminase (eTG/TG3) Antibody, IgA by ELISA

ARUP test code 2010902

Epidermal Transglutaminase Ab IgA, ELISA

See Note

CLINICAL INFORMATION

Skin lesions and gastrointestinal symptoms. Presumptive diagnosis is dermatitis herpetiformis.

Specimen Details

S22-IP0000500 - Serum; Collected: 6/21/2022; Received: 6/22/2022

DIAGNOSTIC INTERPRETATION

Increased IgA epidermal transglutaminase (eTG), also known as transglutaminase 3 (TG3), antibody level by ELISA, providing support for the diagnosis of dermatitis herpetiformis

(See Results and Comments)

RESULTS

Enzyme-Linked Immunosorbent Assay (ELISA)

Epidermal Transglutaminase (eTG/TG3) IgA Antibodies

IgA epidermal transglutaminase antibody level: 55 U/mL (H)

Reference Range:

Normal (negative) = Less than 16 U/mL

Borderline/Indeterminate = 16-22 U/mL

Increased (H) (positive) = Greater than 22 U/mL

COMMENTS

Specific

This ELISA result, demonstrating an increased IgA epidermal transglutaminase (eTG), also known as transglutaminase 3 (TG3), antibody level, supports the diagnosis of dermatitis herpetiformis. Most patients with dermatitis herpetiformis have associated celiac disease.

Clinical correlation is needed including with direct immunofluorescence findings on a biopsy specimen and assessment of celiac disease serologies, including serum IgA endomysial antibodies by indirect immunofluorescence and IgA tissue transglutaminase (tTG), also known as transglutaminase 2 (TG2), antibodies by ELISA. If not already performed, direct immunofluorescence testing can be accomplished on a biopsy specimen submitted through ARUP Laboratories [ARUP test number 0092572, Direct Immunofluorescence, Tissue Biopsy (Cutaneous,

H=High, L=Low, *=Abnormal, C=Critical

Unless otherwise indicated, testing performed at:

ARUP LABORATORIES | 800-522-2787 | aruplab.com
500 Chipeta Way, Salt Lake City, UT 84108-1221
Tracy I. George, MD, Laboratory Director

Patient: PATIENT, POS TEST
ARUP Accession: 22-172-118659
Patient Identifiers: 39634
Visit Number (FIN): 39957
Page 1 of 3 | Printed: 6/22/2022 12:22:03 PM

Mucosal, Epithelial)], and testing for serum celiac disease antibodies may be accomplished by request (ARUP test number 2008114, Celiac Disease Reflexive Cascade); contact ARUP Client Services, 1-800-242-2787, option 2, for assistance.

IgA eTG/TG3 antibody levels correlate with disease activity in individual patients with dermatitis herpetiformis; therefore, monitoring antibody levels may aid in assessing disease activity, including as related to gluten ingestion.

General

Epidermal transglutaminase (eTG), also known as transglutaminase 3 (TG3), is the dominant antigen to which IgA antibodies develop in dermatitis herpetiformis. IgA epidermal transglutaminase antibodies account for the characteristic dermal IgA reactivity (subepithelial granules or fibrils beneath the basement membrane zone with stippling in dermal papillae) observed by direct immunofluorescence in skin biopsy specimens. An increased IgA eTG/TG3 antibody level in serum is distinctly characteristic of dermatitis herpetiformis.

Levels of IgA eTG/TG3 antibodies may correlate with disease activity in individual patients with dermatitis herpetiformis. Most patients with dermatitis herpetiformis have gluten sensitivity with celiac disease and characteristic IgA antibodies to tissue transglutaminase (tTG), also known as transglutaminase 2 (TG2), by ELISA, along with positive IgA endomysial antibodies by indirect immunofluorescence which correlate with disease activity. Patients with dermatitis herpetiformis can have an antibody profile specific for eTG/TG3 with higher avidity than to tTG/TG2; however, a normal IgA eTG/TG3 antibody level does not rule out the diagnosis of dermatitis herpetiformis.

TESTING METHODS

Enzyme-Linked Immunosorbent Assay (ELISA)

IgA epidermal transglutaminase (eTG), also known as transglutaminase 3 (TG3), antibody level in serum determined by ELISA (ALPCO Immunoassays). The performance characteristics of this ELISA testing were determined by the Immunodermatology Laboratory at the University of Utah. The testing has not been cleared or approved by the FDA (US Food and Drug Administration). FDA clearance or approval currently is not required for this testing performed in a CLIA-certified laboratory (Clinical Laboratory Improvement Amendments) and intended for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions. [One ELISA]

Electronically signed by [REDACTED]

Performed At: IMMUNODERMATOLOGY LABORATORY
417 S. WAKARA WAY, SUITE 2151
SALT LAKE CITY, UT 84108
Medical Director: JOHN JOSEPH ZONE, MD
CLIA Number: 46D0681916

EER Epidermal Transglutaminase Ab, IgA

See Note

Authorized individuals can access the ARUP Enhanced Report using the following link:

[REDACTED]

H=High, L=Low, *=Abnormal, C=Critical

Unless otherwise indicated, testing performed at:

ARUP LABORATORIES | 800-522-2787 | aruplab.com
500 Chipeta Way, Salt Lake City, UT 84108-1221
Tracy I. George, MD, Laboratory Director

Patient: PATIENT, POS TEST
ARUP Accession: 22-172-118659
Patient Identifiers: 39634
Visit Number (FIN): 39957
Page 2 of 3 | Printed: 6/22/2022 12:22:03 PM

VERIFIED/REPORTED DATES

Procedure	Accession	Collected	Received	Verified/Reported
Epidermal Transglutaminase Ab IgA, ELISA	22-172-118659	6/21/2022 3:39:00 PM	6/22/2022 10:03:01 AM	6/22/2022 12:04:00 PM
EER Epidermal Transglutaminase Ab, IgA	22-172-118659	6/21/2022 3:39:00 PM	6/22/2022 10:03:01 AM	6/22/2022 10:10:00 AM

END OF CHART

H=High, L=Low, *=Abnormal, C=Critical

Unless otherwise indicated, testing performed at:

ARUP LABORATORIES | 800-522-2787 | aruplab.com
500 Chipeta Way, Salt Lake City, UT 84108-1221
Tracy I. George, MD, Laboratory Director

Patient: PATIENT, POS TEST
ARUP Accession: 22-172-118659
Patient Identifiers: 39634
Visit Number (FIN): 39957
Page 3 of 3 | Printed: 6/22/2022 12:22:03 PM